세계의 재생의료 시장 : 제품, 치료 분야 및 지역별(2024-2031년)

Regenerative Medicine Market Valuation - 2024-2031

Growing public awareness regarding the benefits of preventative and personalized medicine in curbing prevalent chronic diseases such as cancer, central nervous diseases, and others drives the growth potential of the Regenerative Medicine Market. According to the analyst from Verified Market Research, the Regenerative Medicine Market is estimated to reach a valuation of USD 173.49 Billion by 2031, over the forecast by subjugating the revenue of USD 32.71 Billion valued in 2024.

The rising burden of diseases among the growing aging population is a key driver of the Regenerative Medicine Market. The current trend of shifting healthcare landscape is expected to grow over time enabling the market to grow at aCAGR of 23.19% from 2024 to 2031.

Regenerative Medicine Market: Definition/ Overview

Regenerative medicine is an advanced branch of medicine that focuses on using the body's natural ability to heal and repair itself. It involves using modern procedures to stimulate or replace damaged tissues and organs to restore normal function. One important strategy is the utilization of stem cells, which have the unique capacity to differentiate into diverse cell types. In regenerative medicine, scientists and physicians use these cells to repair or replace damaged tissues caused by injury, disease, or aging.

Furthermore, treatments for heart problems and joint injuries, skin regeneration, and even the cultivation of organs for transplantation are just a few of the numerous applications for regenerative medicine. The aim is to transform medical interventions by fostering the body's inherent healing capacities and offering inventive resolutions for diverse health issues.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Prevalence of Chronic Illnesses Skyrocket the Sales of Regenerative Medicine?

The rising prevalence of conditions such as cancer, cardiovascular disease, and neurological disorders demands medicine that stands out by offering the potential for disease modification or even cure, addressing the root causes. As a result, the rising prevalence of chronic diseases poses a key driver resulting in a higher trajectory of growth in the Regenerative Medicine Market.

Rapid advancements in gene editing, stem cell engineering, and 3D bioprinting speed up the development of more effective and tailored medicines. These breakthroughs broaden the variety of treatable illnesses, improve treatment precision, and improve overall patient outcomes, propelling regenerative medicine to mainstream healthcare in the market.

Furthermore, growing government support and funding in the research and development of drug discovery are crucial for the expansion of regenerative medicine. There is also a rise in financial support offered by venture capitalists, pharmaceutical corporations, and government agencies in upsurging the productivity of this kind of medicine. In addition to this, financial stability in the pharmaceutical industry is leading to faster clinical studies, larger patient cohorts, and faster market penetration, all of which contribute to bolstering the growth of the Regenerative Medicine Market.

How are High Production Costs and Complex Manufacturing Processes Favoring the Regenerative Medicines Market?

The complexity of the regulatory systems, combined with safety concerns about cell and gene therapies, makes the authorization process lengthy and costly. Thus, stringent restrictions and lengthy approval processes are barriers restraining the growth of the Regenerative Medicine Market.

Due to the high production costs and intricate manufacturing procedures involved in cell and gene therapies, the Regenerative Medicine Market faces considerable challenges in terms of manufacturing and scalability. The fragile nature of the biological components used adds to the challenge, resulting in higher expenses and limited patient access.

Furthermore, the high expense of these therapies limits patient access and puts pressure on healthcare systems. The immature reimbursement policies and the unwillingness of insurance companies to cover the costs considering high upfront expenditures and short-term data of regenerative medicine are key challenges limiting its adoption.

Category-Wise Acumens

Will Prevalence Of Chronic Diseases Upsurge Application of Cell Therapy?

According to VMR, the cell therapy segment is estimated to hold the largest market share in the Regenerative Medicine Market during the forecast period. The targeted therapeutic potential, versatility, and personalized approach are features anticipated to boost the expansion of the market. The expansion and dominance of cell therapy in this rapidly evolving market are further propelled by the compliance of simplified and advanced procedures with a favorable regulatory environment is bolstering the use of cell therapy. In addition to this, the growing aging population susceptible to various diseases is resulting in an increase in healthcare cost, thereby demanding affordable regenerative medicines like cell therapies.

The versatility of cell therapies in treating a wide range of ailments, from cancer and autoimmune disorders to neurological and cardiovascular conditions, expands their market reach and potential impact, contributing to the segment's dominant position. Also, cell therapies differ from conventional pharmaceuticals as they adopt a focused approach to illness therapy, minimizing systemic effects and increasing efficacy while minimizing negative effects.

Furthermore, improvements in cell culture and manufacturing processes contribute toward enhancing the efficiency and scalability of cell therapy production, thereby resulting in higher accessibility and cost-effectiveness. Such technological advancements serve as an important role in bolstering the cell therapy segment in the Regenerative Medicine Market.

Which Factors Enhance the Use of Regenerative Medicine in Musculoskeletal Problems?

The musculoskeletal disorders segment is estimated to dominate in the Regenerative Medicine Market over the period. The high prevalence of this disease is creating a substantial demand for treatment options. Also, active research and development efforts have resulted in an efficient process of new cell and gene therapy applicants, firmly establishing musculoskeletal disorders as a dominant segment in the Regenerative Medicine Market.

Arthritis, osteoarthritis, sports injuries, and back discomfort affect a large proportion of the global population. The prevalence of musculoskeletal problems results in a sizable and expanding patient population, producing a high demand for effective treatment alternatives. As a result, the Regenerative Medicine Market has naturally oriented toward tackling the most common difficulties related to musculoskeletal disorders influencing the demand for regenerative medicine.

Furthermore, the high ailments associated with musculoskeletal diseases are spurring the demand for innovative treatments to relieve symptoms for providing long-term benefits. Thus, regenerative medicine therapies, with their ability to promote tissue repair and regeneration, offer a promising option for treating the underlying causes of many illnesses. This advantage is likely to enable the musculoskeletal disorder segment to dominate the market.

Country/Region-wise Acumens

How will Well-established Healthcare Infrastructure in North America Drive Regenerative Medicine Market?

According to VMR Analyst, North America is estimated to dominate the Regenerative Medicine Market during the forecast period. The dominance of this segment is attributable to the growing demand for personalized medicine with high compatibility with the current regulatory framework.

Also, the growing number of ailments related to the widespread adoption of social habits such as drinking, smoking, dietary changes, and sedentary lifestyles are leading to an increase in healthcare expenditure. This growing number of diseases among the demographic group, especially the aged population, is stirring the need for accurate and efficient regenerative medicines in the region.

A rising number of people are reaching older age groups, leading to an increased incidence of aging-related chronic disorders in the North American region. Regenerative medicine, with its ability to repair and replace damaged tissues, is ideal for the healthcare needs of an aging population, propelling market growth.

Furthermore, the United States Food and Drug Administration (FDA) established streamlined paths for cell and gene therapy approval, promoting faster regulatory approvals and market access. As a result, North America's advantageous regulatory structure, particularly in the United States, is a key driver of the Regenerative Medicine Market in North America.

What are the Key Drivers Influencing the Adoption of Regenerative Medicine in Asia Pacific?

Asia Pacific is estimated to grow at the highest CAGR in the Regenerative Medicine Market during the forecast period due to the high healthcare spending among large and growing patient populations wanting affordable therapies. This growing focus on using regenerative medicines to treat infectious diseases along with the support and funding of government-driven healthcare initiatives is likely to create a dynamic and developing market landscape with tremendous opportunities for innovation and success in this region.

Individuals and governments are increasingly able to invest in innovative and costly medical technology, such as regenerative medicines. This trend is projected to enable the expansion of the market and facilitate the adoption of innovative treatments in the region, propelling the demand for regenerative medicine.

Furthermore, the frequent occurrence of diseases such as hepatitis and dengue fever increases the demand for effective regenerative therapies in this area. Thus, growing awareness regarding the popularity and potential of regenerative medicine in combating diseases among governments and healthcare organizations in combating infectious diseases, resulting in increased investment and research in this field.

Competitive Landscape

The regenerative medicine sector is a battleground for innovation, with established pharmaceutical giants competing for domination alongside dynamic startups. While large firms have extensive portfolios and established distribution networks, versatile startups provide innovative platforms and individualized treatments. This dynamic landscape offers ongoing evolution and ground-breaking discoveries, delivering an exciting ride for both investors and patients.

Some of the prominent players operating in the Regenerative Medicine Market include:

Johnson & Johnson

Novartis

Roche

AbbVie

Pfizer

Vericel Corporation

Cellular Dynamics International, Editas Medicine

Spark Therapeutics

Bluebird bio

Fate Therapeutics

Autolus Therapeutics

Tmunity Therapeutics

Rocket Pharmaceuticals

Carbios Therapeutics

Regentis

Cellular Bioengineering (CBE) Korea

Athersys Inc.

ReNeuron

Histogenics

Regenerative Medicine Market Latest Developments

In January 2024, Vertex Pharmaceuticals has reported promising Phase 2b data for VX-886, a stem cell therapy for pulmonary fibrosis, showing increased lung function and breathing capacity in patients.

In January 2024, Rocket Pharmaceuticals has initiated a Phase 3 trial for its RVL001 stem cell therapy for alpha-1 antitrypsin deficiency (AATD), a rare genetic liver disease, marking a significant step towards commercialization and providing a potentially life-saving treatment for AATD sufferers.

TABLE OF CONTENTS

1 INTRODUCTION OF THE GLOBAL REGENERATIVE MEDICINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL REGENERATIVE MEDICINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porter's Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL REGENERATIVE MEDICINE MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Therapeutics
• 5.3 Cell Therapy
  • 5.3.1 Stem cell Therapy
  • 5.3.2 Cell Transplantations
• 5.4 Stem cell Therapy Products
• 5.5 Cell-based Immunotherapy Products
• 5.6 Gene Therapy
• 5.7 Tissue Engineering

6 GLOBAL REGENERATIVE MEDICINE MARKET, BY THERAPY AREA

• 6.1 Overview
• 6.2 Oncology
• 6.3 Musculoskeletal Disorders
• 6.4 Dermatology & Wound Care
• 6.5 Cardiovascular Diseases
• 6.6 Ophthalmology
• 6.7 Neurology
• 6.8 Other applications

7 GLOBAL REGENERATIVE MEDICINE MARKET, BY GEOGRAPHY

• 7.1 Overview
• 7.2 North America
  • 7.2.1 The U.S.
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 The U.K.
  • 7.3.3 France
  • 7.3.4 Italy
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 China
  • 7.4.2 Japan
  • 7.4.3 India
  • 7.4.4 Rest of Asia Pacific
• 7.5 Latin America
  • 7.5.1 Brazil
  • 7.5.2 Argentina
  • 7.5.3 Rest of LATAM
• 7.6 Middle East and Africa
  • 7.6.1 UAE
  • 7.6.2 Saudi Arabia
  • 7.6.3 South Africa
  • 7.6.4 Rest of the Middle East and Africa

8 GLOBAL REGENERATIVE MEDICINE MARKET COMPETITIVE LANDSCAPE

• 8.1 Overview
• 8.2 Company Market Ranking
• 8.3 Key Development Strategies
• 8.4 Company Regional Footprint
• 8.5 Company Industry Footprint
• 8.6 ACE Matrix

9 COMPANY PROFILES

• 9.1 Johnson & Johnson
  • 9.1.1 Company Overview
  • 9.1.2 Company Insights
  • 9.1.3 Business Breakdown
  • 9.1.4 Product Benchmarking
  • 9.1.5 Key Developments
  • 9.1.6 Winning Imperatives
  • 9.1.7 Current Focus & Strategies
  • 9.1.8 Threat from Competition
  • 9.1.9 SWOT Analysis
• 9.2 Novartis
  • 9.2.1 Company Overview
  • 9.2.2 Company Insights
  • 9.2.3 Business Breakdown
  • 9.2.4 Product Benchmarking
  • 9.2.5 Key Developments
  • 9.2.6 Winning Imperatives
  • 9.2.7 Current Focus & Strategies
  • 9.2.8 Threat from Competition
  • 9.2.9 SWOT Analysis
• 9.3 Roche
  • 9.3.1 Company Overview
  • 9.3.2 Company Insights
  • 9.3.3 Business Breakdown
  • 9.3.4 Product Benchmarking
  • 9.3.5 Key Developments
  • 9.3.6 Winning Imperatives
  • 9.3.7 Current Focus & Strategies
  • 9.3.8 Threat from Competition
  • 9.3.9 SWOT Analysis
• 9.4 AbbVie
  • 9.4.1 Company Overview
  • 9.4.2 Company Insights
  • 9.4.3 Business Breakdown
  • 9.4.4 Product Benchmarking
  • 9.4.5 Key Developments
  • 9.4.6 Winning Imperatives
  • 9.4.7 Current Focus & Strategies
  • 9.4.8 Threat from Competition
  • 9.4.9 SWOT Analysis
• 9.5 Pfizer
  • 9.5.1 Company Overview
  • 9.5.2 Company Insights
  • 9.5.3 Business Breakdown
  • 9.5.4 Product Benchmarking
  • 9.5.5 Key Developments
  • 9.5.6 Winning Imperatives
  • 9.5.7 Current Focus & Strategies
  • 9.5.8 Threat from Competition
  • 9.5.9 SWOT Analysis
• 9.6 Vericel Corporation
  • 9.6.1 Company Overview
  • 9.6.2 Company Insights
  • 9.6.3 Business Breakdown
  • 9.6.4 Product Benchmarking
  • 9.6.5 Key Developments
  • 9.6.6 Winning Imperatives
  • 9.6.7 Current Focus & Strategies
  • 9.6.8 Threat from Competition
  • 9.6.9 SWOT Analysis
• 9.7 Cellular Dynamics International
  • 9.7.1 Company Overview
  • 9.7.2 Company Insights
  • 9.7.3 Business Breakdown
  • 9.7.4 Product Benchmarking
  • 9.7.5 Key Developments
  • 9.7.6 Winning Imperatives
  • 9.7.7 Current Focus & Strategies
  • 9.7.8 Threat from Competition
  • 9.7.9 SWOT Analysis
• 9.8 Editas Medicine
  • 9.8.1 Company Overview
  • 9.8.2 Company Insights
  • 9.8.3 Business Breakdown
  • 9.8.4 Product Benchmarking
  • 9.8.5 Key Developments
  • 9.8.6 Winning Imperatives
  • 9.8.7 Current Focus & Strategies
  • 9.8.8 Threat from Competition
  • 9.8.9 SWOT Analysis
• 9.9 Spark Therapeutics
  • 9.9.1 Company Overview
  • 9.9.2 Company Insights
  • 9.9.3 Business Breakdown
  • 9.9.4 Product Benchmarking
  • 9.9.5 Key Developments
  • 9.9.6 Winning Imperatives
  • 9.9.7 Current Focus & Strategies
  • 9.9.8 Threat from Competition
  • 9.9.9 SWOT Analysis
• 9.10 Bluebird bio
  • 9.10.1 Company Overview
  • 9.10.2 Company Insights
  • 9.10.3 Business Breakdown
  • 9.10.4 Product Benchmarking
  • 9.10.5 Key Developments
  • 9.10.6 Winning Imperatives
  • 9.10.7 Current Focus & Strategies
  • 9.10.8 Threat from Competition
  • 9.10.9 SWOT Analysis

10 KEY DEVELOPMENTS

• 10.1 Product Launches/Developments
• 10.2 Mergers and Acquisitions
• 10.3 Business Expansions
• 10.4 Partnerships and Collaborations

11 Appendix

• 11.1 Related Research